Beyond OEB5: Is OEB6 really the next standard for high-potency pharma?
Few areas of pharmaceutical manufacturing have attracted as much investment in recent years as high-potency containment. The expansion of oncology…
All articles by Alexander Love
Alexander Love
-
-
Develop site-centric protocols to optimize enrollment and maximize performance
In an attempt to meet regulatory expectations, clinical trials are challenged by highly complex protocol design. But these study plans…
-
Five considerations for adopting AI in clinical study build workflows
Artificial intelligence (AI) is becoming widely adopted in clinical data management, but the most persuasive use cases are rarely the…
-
Post-marketing oncology studies: Enabling faster recruitment and lower costs
Post-marketing approval studies in clinical research for cancer typically suffer from poor engagement and protracted timelines – driving up costs…
-
Peptide drug conjugates: How the Indena and Chemi partnership is delivering
The pharmaceutical industry is investing heavily in therapies capable of delivering high-potent treatments to diseased cells while limiting damage to…
-
Enhance clinical trial screening and improve patient matching accuracy
Traditional approaches to patient-trial matching often rely solely on structured data, leading to inaccurate eligibility lists and missed opportunities to…
-
How price variation impacts employers
This is the first episode in our second season exploring the evolving landscape of real-world data and its role in…
-
Quality by design: The impact of disconnected systems on clinical data
As clinical trials become more digitalised, the data landscape is expanding faster than the processes designed to control it. Electronic…
-
Podcast: The growth of clinical trials and research in Israel
Israel has a robust and growing clinical trials ecosystem. This podcast explores the factors that what make Israel such an…
-
The cost of inefficiencies in clinical trials
Clinical trials are expensive, time-sensitive, and closely monitored, with sponsors and contract research organisations (CROs) under pressure to run studies…